1-7 of 7
Anqi Ma
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Akt Inhibition Differently Controls PRC2 Components and Synergizes with Dual EZH2/1 Inhibitor in the Treatment of Multiple Myeloma

Mohamed Rizk, BSc, MSc, Ola Rizq, MD PhD, Motohiko Oshima, PhD, Yaeko Nakajima-Takagi, PhD, Shuhei Koide, PhD, Atsunori Saraya, Yusuke Isshiki, MD PhD, Tetsuhiro Chiba, MD PhD, Satoshi Yamazaki, PhD, Anqi Ma, PhD, Jian Jin, PhD, Atsushi Iwama, MD PhD, Naoya Mimura, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4400.
https://doi.org/10.1182/blood-2019-122157
Published: 2019
Journal Articles

PHF19 promotes multiple myeloma tumorigenicity through PRC2 activation and broad H3K27me3 domain formation

Zhihong Ren, Jeong Hyun Ahn, Hequn Liu, Yi-Hsuan Tsai, Natarajan V. Bhanu, Brian Koss, David F. Allison, Anqi Ma, Aaron J. Storey, Ping Wang, Samuel G. Mackintosh, Ricky D. Edmondson, Richard W. J. Groen, Anton C. Martens, Benjamin A. Garcia, Alan J. Tackett, Jian Jin, Ling Cai, Deyou Zheng, Gang Greg Wang
Journal: Blood
Blood (2019) 134 (14): 1176–1189.
https://doi.org/10.1182/blood.2019000578
Published: 2019
Includes: Supplemental data
Journal Articles

Hsp90 inhibition destabilizes Ezh2 protein in alloreactive T cells and reduces graft-versus-host disease in mice

Qingrong Huang, Shan He, Yuanyuan Tian, Yuting Gu, Pan Chen, Changhong Li, Jiefang Huang, Yongnian Liu, Hongshuang Yu, Min Jin, Shaoyan Hu, Qing Tong, Anqi Ma, Jian Jin, Elizabeth Hexner, Henry Fung, Ran Reshef, Yi Zhang, Yanyun Zhang
Journal: Blood
Blood (2017) 129 (20): 2737–2748.
https://doi.org/10.1182/blood-2016-08-735886
Published: 2017
Includes: Supplemental data
Journal Articles

SET8 Is a Potential Therapeutic Target in MM

Herviou Laurie, Fanny Izard, Elke De Bruyne, PhD, Eva Desmedt, Anqi Ma, PhD, Jian Jin, PhD, Karin Vanderkerken, PhD, Eric Julien, Jerome Moreaux, PhD
Journal: Blood
Blood (2016) 128 (22): 4435.
https://doi.org/10.1182/blood.V128.22.4435.4435
Published: 2016
Journal Articles

Molecular Mechanism behind the Synergistic Activity of Proteasome Inhibition and PRC2 Inhibition in the Treatment of Multiple Myeloma

Ola Rizq, MD, Naoya Mimura, MD PhD, Motohiko Oshima, PhD, Atsunori Saraya, Shuhei Koide, PhD, Yuko Kato, PhD, Kazumasa Aoyama, PhD, Yaeko Nakajima-Takagi, PhD, Changshan Wang, PhD, Anqi Ma, Jian Jin, PhD, Tohru Iseki, MD PhD, Chiaki Nakaseko, MD, PhD, Atsushi Iwama, MD PhD
Journal: Blood
Blood (2016) 128 (22): 312.
https://doi.org/10.1182/blood.V128.22.312.312
Published: 2016
Journal Articles

Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL- rearranged leukemia

Bowen Xu, Doan M. On, Anqi Ma, Trevor Parton, Kyle D. Konze, Samantha G. Pattenden, David F. Allison, Ling Cai, Shira Rockowitz, Shichong Liu, Ying Liu, Fengling Li, Masoud Vedadi, Stephen V. Frye, Benjamin A. Garcia, Deyou Zheng, Jian Jin, Gang Greg Wang
Journal: Blood
Blood (2015) 125 (2): 346–357.
https://doi.org/10.1182/blood-2014-06-581082
Published: 2015
Includes: Supplemental data
Journal Articles

EZH2 Inhibition and the Combination with Proteasome Inhibition Are Novel Potential Strategies for the Treatment of Multiple Myeloma

Ola Rizq, Naoya Mimura, MD PhD, Shuhei Koide, Anqi Ma, PhD, Jian Jin, PhD, Tohru Iseki, MD PhD, Chiaki Nakaseko, MD PhD, Atsushi Iwama, MD PhD
Journal: Blood
Blood (2014) 124 (21): 2094.
https://doi.org/10.1182/blood.V124.21.2094.2094
Published: 2014